Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 8, 2004 - Issue 5
Submit an article Journal homepage
146
Views
34
CrossRef citations to date
0
Altmetric
Review

Potassium channel subtypes as molecular targets for overactive bladder and other urological disorders

Murali Gopalakrishnan Abbott Laboratories, Neuroscience Research, Global Pharmaceutical Research and Development, Building AP9A, 3rd floor, 100 Abbott Park Road, Abbott Park, Illinois, 60064, USA. [email protected]
&
Char-Chang Shieh Abbott Laboratories, Neuroscience Research, Global Pharmaceutical Research and Development, Building AP9A, 3rd floor, 100 Abbott Park Road, Abbott Park, Illinois, 60064, USA. [email protected]
Pages 437-458 | Published online: 25 Feb 2005

Bibliography

  • MORELAND RB, BRIONI JD, SULLIVAN JP: Emerging pharmacologic approaches for the treatment of lower urinary tract disorders. Pharinacol Exp. The]: (2004) 308:797–804.
  • YOSHIMURA N, CHANCELLOR MB: Current and future pharmacological treatment for overactive bladder. Urol (2002) 168:1897–1913.
  • MICHEL MC, BRIONI JD: Meeting report for the ASPET Ray Fuller symposium: lower uinary tract disorders: physiology, pharmacology, and therapeutic approaches. J. Phannacol Exp. Ther. (2002) 303:431–437.
  • PAPAZIAN DM, SCHWARZ TL, TEMPEL BL, JAN YN, JAN LY: Cloning of genomic and complementary DNA from Shaker, a putative potassium channel gene from Drosophila.Science (1987) 237:749–753.
  • •Initial cloning of a voltage-gated IQ- channel.
  • SHIEH CC, COGHLAN M, SULLIVAN JP, GOPALAKRISHNAN M: Potassium channels: molecular defects, diseases, and therapeutic opportunities. Pharinacol Rev (2000) 52:557–594.
  • COGHLAN MJ, CARROLL WA, GOPALAKRISHNAN M: Recent developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress. J. Med. Chem. (2001) 44:1627–1653.
  • BRADING AF: A myogenic basis for theoveractive bladder. Urology (1997) 50:57-67; discussion 68–73.
  • •A comprehensive review on the myogenic basis of overactive bladder.
  • HASHITANI H, FUKUTA H, TAKANO H, KLEMM ME SUZUKI H: Origin and propagation of spontaneous excitation in smooth muscle of the guinea-pig urinary bladder. J. Physiol. (2001) 530:273–286.
  • ••Simultaneous measurement ofspontaneous action potential and changes in intracellular Ca2' concentration in guinea-pig bladder smooth muscle, leading to the suggestion that spontaneous action potentials and associated calcium waves occur almost simultaneously along the boundary of smooth muscle bundles and then propagate, probably through gap junctions.
  • KLOCKNER U, ISENBERG G: Action potentials and net membrane currents of isolated smooth muscle cells (urinary bladder of the guinea-pig). Flingers Arch. (1985) 405:329–339.
  • GALLEGOS CR, FRY CH: Alterations to the electrophysiology of isolated human detrusor smooth muscle cells in bladder disease. I Ural. (1994) 151:754–758.
  • HEPPNER TJ, BONEV AD, NELSON MT: Ca2'-activated K.' channels regulate action potential repolarization in urinary bladder smooth muscle. Ain. Physiol (1997) 273:C110–C117.
  • HERRERA GM, NELSON MT: Differential regulation of SK and BK channels by Ca2' signals from Ca2' channels and ryanodine receptors in guinea-pig urinary bladder myocytes. I Physic] (2002) 541:483–492.
  • THORNELOE KS, NELSON MT: Properties and molecular basis of the mouse urinary bladder voltage-gated K.' current. Physiol (2003) 549:65–74.
  • ••Reveals the molecular identities ofvoltage-gated I(' channels in bladder smooth muscle using molecular biology, electrophysiology and pharmacological approaches.
  • HASHITANI H, BRADING AF: Ionic basis for the regulation of spontaneous excitation in detrusor smooth muscle cells of the guinea-pig urinary bladder. Br. J. Phannacol (2003) 140:159–169.
  • •Using intracellular microelectrode recording and tension measurement, in combination with pharmacological approaches, this study revealed the roles of voltage-gated K+ Bk., Sk. and Ca2+ channels in spontaneous activity.
  • FUJII K, FOSTER CD, BRADING AF, PAREKH AB: Potassium channel blockers and the effects of cromakalim on the smooth muscle of the guinea-pig bladder. Br. J. Phannacol (1990) 99:779–785.
  • DAVIES AM, BATCHELOR TJ, EARDLEY I, BEECH DJ: Potassium channel Kv al subunit expression and function in human detrusor muscle. J. Um]. (2002) 167:1881–1886.
  • OHYA S, TANAKA M, WATANABE M, MAIZUMI Y: Diverse expression of delayed rectifier K.' channel subtype transcripts in several types of smooth muscles of the rat. J. Smooth Muscle Res. (2000) 36:101–115.
  • OHI Y, YAMAMURA H, NAGANO N et al.: Local Ca2+ transients and distribution of BK channels and ryanodine receptors in smooth muscle cells of guinea-pig vas deferens and urinary bladder. I Physiol (2001) 534:313–326.
  • IMAIZUMI Y, TORII Y, OHI Y et al.: Ca2' images and K* current during depolarization in smooth muscle cells of the guinea-pig vas deferens and urinary bladder. Physiol (1998) 510:705–719.
  • HERRERA GM, HEPPNER TJ, NELSON MT: Regulation of urinary bladder smooth muscle contractions by ryanodine receptors and BK and SK channels. Am. I Physic] Regal Integi: Comp. Physic] (2000) 279:R60–R68.
  • HERRERA GM, HEPPNER TJ, NELSON MT: Voltage dependence of the coupling of Ca2+ sparks to BKca channels in urinary bladder smooth muscle. Ain. Physiol, Cell Physiol (2001) 280:C481–C490.
  • •First study of voltage-dependent coupling of Ca2+ sparks to Bk. channel activity in urinary bladder smooth muscle cells.
  • MCMANUS OB, HELMS LM, PALLANCK L, GANETZKY B, SWANSON R, LEONARD RJ: Functional role of the 13 subunit of high conductance calcium-activated potassium channels. Neuron (1995) 14:645–650.
  • NIMIGEAN CM, MAGLEBY KL: The 13 subunit increases the Ca2+ sensitivity of large conductance Ca2'-activated potassium channels by retaining the gating in the bursting states. I Gen. Physic] (1999) 113:425–440.
  • COX DH, ALDRICH RW: Role of the 131 subunit in large-conductance Ca2+-activated K.+ channel gating energetics. Mechanisms of enhanced Ca2' sensitivity. Gen. Physiol (2000) 116:411–432.
  • PETKOV GV, BONEV AD, HEPPNERTJ, BRENNER R, ALDRICH RW, NELSON MT: I31-subunit of the Ca2+-activated K* channel regulates contractile activity of mouse urinary bladder smooth muscle. Physic] (2001) 537:443–452.
  • ••Using 131 knockout mice, this studydetermined the role of the 131 subunit of Bk. channels in the regulation of urinary bladder smooth muscle activity.
  • CHRIST GJ, DAY NS, SANTIZO C et al.: Bladder instillation of 'naked' hSlo/ pcDNA3 ameliorates detrusor hyperactivity in obstructed rats in vivo. Urology (2001) 57:111.
  • ••First report to show that gene transfectionwith Bk. subunits can suppress detrusor hyperactivity in obstructed rat.
  • BUCKNER SA, MILICIC I, DAZA A et al.: Pharmacological and molecular analysis of ATP-sensitive K* channels in the pig and human detrusor. Eur. Pharmacol (2000) 400:287–295.
  • HASHITANI H, BRADING AF: Electrical properties of detrusor smooth muscles from the pig and human urinary bladder. Br. Pharmacol (2003) 140:146–158.
  • KOHLER M, HIRSCHBERG B, BOND CT et al.: Small-conductance, calcium-activated potassium channels from mammalian brain. Science (1996) 273:1709–1714.
  • •Report of initial cloning of a Sk. channel.
  • HERRERA GM, POZO MJ, ZVARA P et al.: Urinary bladder instability induced by selective suppression of the murine small conductance calcium-activated potassium (SU) channel. J. Physic] (2003) 551:893–903.
  • ••Using the conditional gene expressionapproach, this study demonstrated that overexpression of SK, resulted in greater bladder capacity and urine output.
  • ISHII TM, SILVIA C, HIRSCHBERG B, BOND CT, ADELMAN JP, MAYLIE J: A human intermediate conductance calcium-activated potassium channel. Proc. Natl. Acad. Sci. USA (1997) 94:11651–11656.
  • •Report of the initial cloning of a human Ik. channel.
  • OHYA S, KIMURA S, KITSUKAWA M, MURAKI K, WATANABE M, IMAIZUMI Y: 5K4 encodes intermediate conductance Ca2'-activated K* channels in mouse urinary bladder smooth muscle cells. fpn. I Pharmacol (2000) 84:97–100.
  • NEYLON CB, LANG RJ, FU Y, BOBIK A, REINHART PH: Molecular cloning and characterization of the intermediate-conductance Ca2'-activated K.+ channel in vascular smooth muscle: relationship between K(Ca) channel diversity and smooth muscle cell function. Circ. Res. (1999) 85:e33–e43.
  • SHYNG S, NICHOLS CG: Octameric stoichiometry of the KATp channel complex. I Gen. Physic] (1997) 110:655–664.
  • •One of the first studies to demonstrate the subunit composition of the KATp channel.
  • ISOMOTO S, KONDO C, YAMADA M et al.: A novel sulfonylurea receptor forms with BIR (1c6.2) a smooth muscle type ATP-sensitive K* channel. I Biol. Chem. (1996) 271:24321–24324.
  • •Reported initial cloning of smooth muscle-type KATp channel.
  • YAMADA M, ISOMOTO S, MATSUMOTO S et al: Sulphonylurea receptor 2B and Ki,.6.1 form a sulphonylurea-sensitive but ATP-insensitive K.* channel. I. Physiol (1997) 499:715–720.
  • •Defmed molecular determinants of nucleotide diphosphate-dependent I( channel in vascular smooth muscle cells.
  • GOPALAKRISHNAN M, WHITEAKER KL, MOLINARI EJ et al.: Characterization of the ATP-sensitive potassium channels (KATO expressed in guinea pig bladder smooth muscle cells. Phartnacol Exp. Titer. (1999) 289:551–558.
  • •Characterised pharmacological profile of KATp channels using fluorescent imaging plate reader-based membrane potential techniques and defmed KATp channel components in guinea-pig detrusor.
  • CHUTKOW WA, MAKIELSKI JC, NELSON DJ, BURANT CE FAN Z: Alternative splicing of sur2 exon 17 regulates nucleotide sensitivity of the ATP-sensitive potassium channel. Biol. Chem. (1999) 274:13656–13665.
  • DAVIS-TABER R, CHOI W, FENG J et al.: Molecular characterization of human SUR2-containing KNIT channels. Gene (2000) 256:261–270.
  • SCOTT VE, DAVIS-TABER RA, SILVIA C et al.: Characterization of human urinary bladder KNIT channels containing SUR2B splice variants expressed in L-cells. Ear' Phartnacol (2004) 483:195–205.
  • DE GROAT WC: A neurologic basis for the overactive bladder. Urology (1997) 50:36-52; discussion 53–56.
  • •A comprehensive review on the neurogenic basis of overactive bladder.
  • WEIN AJ: Pharmacological agents for the treatment of urinary incontinence due to overactive bladder. Expert Opin. Investig. Drugs (2001) 10:65–83.
  • BLOK BF: Central pathways controlling micturition and urinary continence. Urology (2002) 59:13–17.
  • ANDERSSON KE: Bladder activation: afferent mechanisms. Urology (2002) 59:43–50.
  • ABRAMS P, CARDOZO L, FALL M et al.:The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn. (2002) 21:167–178.
  • DE GROAT WC, NADELHAFT I, MILNE RJ, BOOTH AM, MORGAN C, THOR K: Organization of the sacral parasympathetic reflex pathways to the urinary bladder and large intestine. .1 Acton. Nerv. Syst. (1981) 3:135–160.
  • HABLER HJ, JANIG W, KOLTZENBURG M: Receptive properties of myelinated primary afferents innervating the inflamed urinary bladder of the cat. Neurophysiol (1993) 69:395–405.
  • HABLER HJ, JANIG W, KOLTZENBURG M: Activation of unmyelinated afferent fibres by mechanical stimuli and inflammation of the urinary bladder in the cat. Physiol (1990) 425:545–562.
  • MAZIERES L, JIANG C, LINDSTROM S: The C fibre reflex of the cat urinary bladder. Physiol (1998) 513:531–541.
  • JIANG CH, MAZIERES L, LINDSTROM S: Cold- and menthol-sensitive C afferents of cat urinary bladder. Physiol (2002) 543:211–220.
  • FOWLER CJ, JEWKES D, MCDONALD WI, LYNN B, DE GROAT WC: Intravesical capsaicin for neurogenic bladder dysfunction. Lancet (1992) 339:1239.
  • •One of the first studies indicating the potential use of capsaicin in the treatment of neurogenic bladder dysfunction.
  • SILVA C, RIBEIRO MJ, CRUZ F: The effect of intravesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contractions are triggered by C-fiber input. Um] (2002) 168:575–579.
  • IGAWA Y, SATOH T, MIZUSAWA H et al.: The role of capsaicin-sensitive afferents in autonomic dysreflexia in patients with spinal cord injury. BIU Int. (2003) 91:637–641.
  • LOWE EM, ANAND P, TERENGHI G, WILLIAMS-CHESTNUT RE, SINICROPI DV, OSBORNE JL: Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Um] (1997) 79:572–577.
  • VIZZARD MA: Changes in urinary bladder neurotrophic factor mRNA and NGF protein following urinary bladder dysfunction. Exp. Neurol (2000) 161:273–284.
  • DUPONT MC, SPITSBERGEN JM, KIM KB, TUTTLE JB, STEERS WD: Histological and neurotrophic changes triggered by varying models of bladder inflammation. Um] (2001) 166:1111–1118.
  • YOSHIMURA N, DE GROAT WC: Increased excitability of afferent neurons innervating rat urinary bladder after chronic bladder inflammation. NeuroscL (1999) 19:4644–4653.
  • DRAKE MJ, HEDLUND P, MILLS IW et al.: Structural and functional denervation of human detrusor after spinal cord injury. Lab. Invest. (2000) 80:1491–1499.
  • •A comprehensive analysis of denervation of human detrusor from patients with spinal cord injury.
  • DRAKE MJ, GARDNER BP, BRADING AF: Innervation of the detrusor muscle bundle in neurogenic detrusor overactivity. RAI Int. (2003) 91:702–710.
  • SOMOGYI GT, ZERNOVA GV, YOSHIYAMA M, ROCHA JN, SMITH CP, DE GROAT WC: Change in muscarinic modulation of transmitter release in the rat urinary bladder after spinal cord injury. Neurochetn. Int. (2003) 43:73–77.
  • MILLS IW, GREENLAND JE, MCMURRAY G et al: Studies of the pathophysiology of idiopathic detrusor instability: the physiological properties of the detrusor smooth muscle and its pattern of innervation. Um] (2000) 163:646–651.
  • •Demonstrated fundamental abnormality including evidence of altered spontaneous contractile activity at the level of the bladder wall in patients with idiopathic detrusor instability.
  • MILLS IW, NOBLE JG, BRADING AF: Radiotelemetered cystometry in pigs: validation and comparison of natural filling versus diuresis cystometry. Um] (2000) 164:1745–1750.
  • ••Using radiotelemetered cystometryrecording in conscious animals, this paper revealed that natural bladder filling results in a higher maximum detrusor pressure during voiding, higher detrusor pressure after contractions, and more frequent detection of unstable contractions in pigs with detrusor instability secondary to partial bladder outflow obstruction, compared to controls.
  • FEY TA, GOPALAKRISHNAN M, STRAKE JG et al: Effects of ATP-sensitive K.* channel openers and tolterodine on involuntary bladder contractions in a pig model of partial bladder outlet obstruction. Neurourol Urodyn. (2003) 22:147–155.
  • •Using telemetry transmitter implantation approaches, this paper demonstrated that KCOs effectively reduced spontaneous non-voiding contraction in bladder with partial outflow obstruction.
  • HAEFLIGERJA, TISSIERES P, TAWADROS T et al.: Connexins 43 and 26 are differentially increased after rat bladder outlet obstruction. Exp. Cell Res. (2002) 274:216–225.
  • CHRIST GJ, DAY NS, DAY M et al: Increased connexin43-mediated intercellular communication in a rat model of bladder overactivity in vivo. Am. I Physiol. Regul Integr. Comp. Physiol. (2003) 284:R1241–R1248.
  • SUI GP, COPPEN SR, DUPONT E et al: Impedance measurements and connexin expression in human detrusor muscle from stable and unstable bladders. BIU Int. (2003) 92:297–305.
  • DISANTO ME, STEIN R, CHANG S et al.: Alteration in the expression of myosin isoforms in detrusor smooth muscle following bladder outlet obstruction. Ain. J. Physiol. Cell Physiol (2003) 30:30.
  • UVELIUS B, ARNER A: Changed metabolism of detrusor muscle cells from obstructed rat urinary bladder. Scand. j Um]. Nephrol Sapp]. (1997) 184:59–65.
  • PARK JM, YANG T, AREND LJ, SMART AM, SCHNERMANN JB, BRIGGS JP: Cyclooxygenase-2 is expressed in bladder during fetal development and stimulated by outlet obstruction. Am. J. Physiol. (1997) 273:F538–F544.
  • QUAYLE JM, NELSON MT, STANDEN NB: ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physic] Rev (1997) 77:1165–232.
  • •A comprehensive review of K AT p channels in smooth muscle.
  • BUCKNER SA, MILICIC I, DAZA AV, COGHLAN MJ, GOPALAKRISHNAN M: Spontaneous phasic activity of the pig urinary bladder smooth muscle: characteristics and sensitivity to potassium channel modulators. Br. J. Pharmacol (2002) 135:639–648.
  • •Describes the influence of urotheliurn, Ca2', Bk. and KATp channels on spontaneous contraction of the pig detrusor.
  • LU SH, YAMAGATA T, ATSUKI K et al.: Effect of KW-7158, a putative afferent nerve inhibitor, on bladder and vesico-vascular reflexes in rat. Brain Res. (2002) 946:72–78.
  • SCULPTOREANU A, YOSHIMURA N, DE GROAT WC: KW-7158 enhances A-type K+ currents in neurons of the dorsal root ganglion of the adult rat. J. Pharmacol. Exp. Ther. (2004) 310(1):159–168.
  • NURSE DE, RESTORICK JM, MUNDY AR: The effect of cromakalim on the normal and hyper-reflexic human detrusor muscle. Br: J. Urol (1991) 68:27–31.
  • KOMERSOVA K, ROGERSON JW, CONWAY EL et al.: The effect of levcromakalim (BRL 38227) on bladder function in patients with high spinal cord lesions. Br. I Clin. Pharmacol (1995) 39:207–209.
  • HEDLUND H, MATTIASSON A, ANDERSSON KE: Effects of pinacidil on detrusor instability in men with bladder outlet obstruction. Um]. (1991) 146:1345–1347.
  • SUDOH K, MASUDA N, UCHIDA W: Different effect of anticholinergic agents and potassium channel openers on urinary bladder response to pelvic nerve stimulation in anaesthetized dogs. J. Amon. Pharmacol (1997) 17:91–96.
  • MASUDA N, UCHIDA W, SHIRAI Y, SHIBASAKI K, GOTO K, TAKENAKA T: Effect of the potassium channel opener YM934 on the contractile response to electrical field stimulation in pig detrusor smooth muscle. J. Um]. (1995) 154:1914–1920.
  • CHESS-WILLIAMS R, MARTIN SW, KORSTANJE C, CHAPPLE CR: In vitro investigation of the bladder-vascular selectivity of levcromakalim and YM934 in human tissues. BIU Int. (1999) 83:1050–1054.
  • BURGGRAAF J, SCHOEMAKER RC, TERPSTRA IJ, COHEN AF: A Phase I double-blind, placebo-controlled, single rising dose study to determine the safety, tolerability, and pharmacokinetics of oral YM934 in healthy male volunteers. Clin. Pharmacol (1998) 38:45–53.
  • HOWE BB, HALTERMAN TJ, YOCHIM CL et al.: ZENECA ZD6169: a novel KATp channel opener with in vivo selectivity for urinary bladder. J. Pharmacy] Exp. Ther. (1995) 274:884–890.
  • PANDITA RK, PERSSON K, ANDERSSON KE: Effects of the K.' channel opener, ZD6169, on volume and PGE2-stimulated bladder activity in conscious rats. Um]. (1997) 158:2300–2304.
  • PANDITA RK, ANDERSSON KE: Effects of intravesical administration of the K.' channel opener, ZD6169, in conscious rats with and without bladder outflow obstruction. Urol. (1999) 162:943–948.
  • YU Y, DE GROAT WC: Effects of ZD6169, a KATp channel opener, on bladder hyperactivity and spinal c-fos expression evoked by bladder irritation in rats. Brain Res. (1998) 807:11–18.
  • YU Y, FRASER MO, DE GROAT WC: Effects of ZD6169, a KATp channel opener, on neurally-mediated plasma extravasation in the rat urinary bladder induced by chemical or electrical stimulation of nerves. Brain Res. (2004) 996:41–46.
  • YU Y, DE GROAT WC: Effects of ZD6169, a KATp channel opener, on the micturition reflex in the rat. Pharmacol Exp. Ther. (1999) 290:825–831.
  • HU S, KIM HS: Modulation of ATP-sensitive and large-conductance Ca2'-activated K.' channels by Zeneca ZD6169 in guinea pig bladder smooth muscle cells. Pharmacol Exp. The]: (1997) 280:38–45.
  • TERAMOTO N, YUNOKI T, IKAWA S et al.: The involvement of L-type Ca2' channels in the relaxant effects of the ATP-sensitive K.' channel opener ZD6169 on pig urethral smooth muscle. Br. J. Pharmacol. (2001) 134:1505–1515.
  • ABDEL-KARIM AM, BIALECKI RA, ELHILALI MM: Effects of ZD6169 and ZD0947, 2 potassium adenosine triphosphate channel openers, on bladder function of spinalized rats. Um]. (2002) 168:837–842.
  • WOJDAN A, FREEDEN C, WOODS M et al: Comparison of the potassium channel openers, WAY-133537, ZD6169, and celikalim on isolated bladder tissue and in vivo bladder instability in rat. Pharmacol Exp. Ther. (1999) 289:1410–1418.
  • LI JH, YASAY GD, KAU ST et al: Studies of the K(ATP) channel opening activity of the new dihydropyridine compound 9-(3-cyanopheny1)-3,4,6,7,9,10-hexahydro-1,8-(2H,5H)-acridined lone in bladder detrusor M vitro. Arzneimittelforschung (1996) 46:525–530.
  • GOPALAKRISHNAN M, BUCKNER SA, WHITEAKER KL et al.: () (9S) 9 (3 Bromo-4-fluoropheny1)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quin olin-8(4H)-one 1,1-dioxide (A-278637): a novel ATP-sensitive potassium channel opener efficacious in suppressing urinary bladder contractions. I. In vitro characterization. Pharmacol Exp. Thec (2002) 303:379–386.
  • BRUNE ME, FEY TA, BRIONI JD et al: () (9S) 9 (3 Bromo-4-fluoropheny1)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quin olin-8(4H)-one 1,1-dioxide (A-278637): a novel ATP-sensitive potassium channel opener efficacious in suppressing urinary bladder contractions. II. In vivo characterization. Pharmacol Exp. Thec (2002) 303:387–394.
  • •This report demonstrated the in vivo potency and bladder selectivity of A-278637 in a pig model of bladder instability secondary to partial bladder outlet obstruction.
  • GOPALAKRISHNAN M: Recent advancesin potassium channel openers. ASPET-Ray Fuller Symposium New Drugs: Bench to Bedside: Diseases of Aging I. Symposium on 'Lower urinary tract disorders: Physiology, Pharmacology and Therapeutic Approaches, July 6–7 2002.
  • TURNER SC, CARROLL WA, WHITE TK et al.: Structure-activity relationship of a novel class of naphthyl amide KATp channel openers. Bioorg. Med. Chem. Lett. (2003) 13:1741–1744.
  • GOPALAKRISHAN M, BUCKNER SA, SHIEH CC et al: In vitro and in vivo characterization of a novel naphthyl amide ATP-sensitive K.+ channel opener, A-151892. Br: J. Pharmacol (2004) 143:81–90.
  • PEREZ-MEDRANO A, BUCKNER SA, COGHLAN MJ et al: Design and synthesis of novel cyanoguanidine ATP-sensitive potassium channel openers for the treatment of overactive bladder. Bioorg. Med. Chem. Lett. (2004) 14:397–400.
  • CHANG WM, BOHM RA, STRAUSS JC et al.: Muscle-specific transcriptional regulation of the slowpoke Ca2'-activated K+ channel gene. Biol. Chem. (2000) 275:3991–3998.
  • BECKER MN, BRENNER R, ATKINSON NS: Tissue-specific expression of a Drosophila calcium-activated potassium channel. Neurosci. (1995) 15:6250–6259.
  • ZHANG XF, GOPALAKRISHNAN M, SHIEH CC: Modulation of action potential firing by iberiotoxin and NS1619 in rat
  • •Report of suppression of sensory neuronal firing by NS1619.
  • MCMANUS OB, HARRIS GH, GIANGIACOMO KM et al.: An activator (1993) 32:6128–6133.
  • OLESEN SP, MUNCH E, MOLDT P, DREJER J: Selective activation of Ca2'-dependent K' channels by novel
  • OLESEN SP, MUNCH E, WATJEN F, DREJER J, MOLDT P: NS 004 - an activator of Ca2+-dependent K+ channels
  • YAMAMURA H, OHI Y, MURAKI K, WATANABE M, IMAIZUMI Y: calcium-sensitive potassium channels to NS1619-induced relaxation in human pregnant myometrium. Hum. Reprod.
  • HUANG Y, LAU CW, HO IH: NS 1619 activates Ca2+-activated K+ currents in rat vas deferens. Eur.j Pharmacol (1997) 325:21–27.
  • SHELDON JH, NORTON NW, ARGENTIERI TM: Inhibition of guinea pig detrusor contraction by NS-1619 is associated with activation of BK, and inhibition of calcium currents. Pharmacol Exp. Ther. (1997) 283:1193–200.
  • HOLLAND M, LANGTON PD, STANDEN NB, BOYLE JP: Effects of the BK, channel activator, NS1619, on rat cerebral artery smooth muscle. Br. .1. Pharmacol (1996) 117:119–129.
  • Ha EDWARDS G, NIEDERSTE-HOLLENBERG A, SCHNEIDER J et al.: Ion channel modulation by NS 1619, the putative BKca channel opener, in vascular smooth muscle. Br. J. Pharmacol (1994) 113:1538–1547.
  • STROBAEK D, CHRISTOPHERSEN P, HOLM NR et al: Modulation of the Ca2'-dependent K.' channel, hslo, by the substituted diphenylurea NS 1608, paxilfine and internal Ca2'. Neuropharmacology (1996) 35:903–914.
  • AHRING PK, STROBAEK D, CHRISTOPHERSEN P et al.: Stable expression of the human large-conductance Ca2'-activated K+ channel a- and 13-subunits in HEK293 cells. FEBS Lett. (1997) 415:67-70. SIEMER C, BUSHFIELD M, NEWGREEN D, GRISSMER S: Effects of NS1608 on MaxiK channels in smooth muscle cells from urinary bladder. Membr: Biol. (2000) 173:57-66. HU S, FINK CA, KIM HS, LAPPE RW: Novel and potent BK channel openers: CGS 7181 and its analogs. Drug Dev. Res. (1997) 41:10-21. TANAKA M, SASAKI Y, HUKUI T et al.: A novel pyrrole derivative, NS-8, activates the Ca2+-sensitive K.+ channels and suppresses micturition reflex in rats. Urol (1998) 159(Suppl.):21. TANAKA M, SASAKI Y, KIMURA Y, FUKUI T, HAMADA K, UKAI Y: A novel pyrrole derivative, NS-8, suppresses the rat micturition reflex by inhibiting afferent pelvic nerve activity. BILI Int. (2003) 92:1031–1036.
  • HEWAWASAM P, ERWAY M, THALODY G et al.: The synthesis and structure-activity relationships of 1,3-diaryl 1,2,4-(4H)-triazol-5-ones: a new class of calcium-dependent, large conductance, potassium (maxi-K) channel opener targeted for urge urinary incontinence. Bioorg. Med. Chem. Lett. (2002) 12:1117–1120.
  • HEWAWASAM P, FAN W, DING M et al: 4-Aryl-3-(hydroxyalkyl)quinolin-2-ones: novel maxi-K channel opening relaxants of corporal smooth muscle targeted for erectile dysfunction. J. Med. Chem. (2003) 46:2819–2822.
  • GRIBKOFF VK, STARRETT JE Jr, DWORETZKY SI et al.: Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nat. Med. (2001) 7:471–477.
  • LI Y, JOHNSON G, ROMINE JL et al: Novel openers of Ca2'-dependent large-conductance potassium channels: symmetrical pharmacophore and electrophysiological evaluation of bisphenols. Bioorg. Med. Chem. Lett. (2003) 13:1437–1439.
  • SCHRODER RL, JESPERSEN T, CHRISTOPHERSEN P, STROBAEK D, JENSEN BS, OLESEN SP: KCNQ4 channel activation by BMS-204352 and retigabine. Neuropharmacology (2001) 40:888–898.
  • DUPUIS DS, SCHRODER RL, JESPERSEN T et al: Activation of KCNQ5 channels stably expressed in HEK293 cells by BMS-204352. Eur.j Pharmacol (2002) 437:129–137.
  • SCHRODER RL, STROBAEK D, OLESEN SP, CHRISTOPHERSEN P, JESPERSEN T, JENSEN BS: Voltage-independent KCNQ4 currents induced by (+/-)BMS-204352. Pflugers Arch. (2003) 446:607–616.
  • TURNER SC, CARROLL WA, WHITE TK et al.: The discovery of a new class of large-conductance Ca2'-activated K.' channel opener targeted for overactive bladder: synthesis and structure-activity relationships of 2-amino-4-azaindoles. Bioorg. Med. Chem. Lett. (2003) 13:2003–2007.
  • MALYSZ J, BUCKNER SA, DAZA AV, MILICIC I, PEREZ-MEDRANO A, GOPALAKRISHNAN M: Functional characterization of large conductance calcium-activated K' channel openers in bladder and vascular smooth muscle. Naunyn Schmiedebergs Arch. Pharmacol (2004).
  • JENTSCH TJ: Neuronal KCNQ potassium channels: physiology and role in disease. Nat. Rev NeuroscL (2000) 1:21–30.
  • COOPER EC, JAN LY: M-channels: neurological diseases, neuromodulation, and drug development. Arch. Neurol (2003) 60:496–500.
  • GRIBKOFF VK: The therapeutic potential of neuronal KCNQ channel modulators. Expert Opin. Tiler. Targets (2003) 7:737–748.
  • •A comprehensive review of the therapeutic potential of neuronal KCNQ channels.
  • SHLEDON JH, DAVIS A, NORTON NW et al: Evidence of KCNQ gene expression and M-current activity in rat and human urinary bladder smooth muscle. In: The ASPET-Ray Fuller Symposium Series: Lower Urinary Tract Disorders: Physiology pharmacology and therapeutic approches. San Francisco, USA (2002). Abstract.
  • MAIN MJ, CRYAN JE, DUPERE JR, COX B, CLARE JJ, BURBIDGE SA: Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol (2000) 58:253–262.
  • TATULIAN L, DELMAS P, ABOGADIE FC, BROWN DA: Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. Neurosci. (2001) 21:5535–5545.
  • WICKENDEN AD, YU W ZOU A, JEGLA T, WAGONER PK: Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol (2000) 58:591–600.
  • RUNDFELDT C, NETZER R: The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits. Neurosci. Lett. (2000) 282:73–76.
  • WU YJ, DAVIS CD, DWORETZKY S et al.: Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: Identification of (S) N [1 (4 fluoro-3-morpholin-4-ylphenyl)ethyll 3 (4 fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition. J. Med. Chem. (2003) 46:3778–3781.
  • WU YJ, BOISSARD CG, GRECO C et al: (S)-N- [1- (3-Morpholin-4-ylphenyl) 3-phenylacrylamide: an orally bioavailable KCNQ2 opener with significant activity in a cortical spreading depression model of migraine. j. Med. Chem. (2003) 46:3197–3200.
  • GRONBERG H: Prostate cancer epidemiology. Lancet (2003) 361:859–864.
  • SMITH JR, FREIJE D, CARPTEN JD et al.: Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (1996) 274:1371–374.
  • ••Provided evidence of a link betweenmajor prostate cancer susceptibility and chromosome 1.
  • COONEY KA, MCCARTHY JD, LANGE E et al: Prostate cancer susceptibility locus on chromosome lq: a confirmatory study. Natl. Cancer Inst. (1997) 89:955–959.
  • BERTHON P, VALERI A, COHEN-AKENINE A et al: Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am. Hum. Genet. (1998) 62:1416–1424.
  • XU J, MEYERS D, FREIJE D et al: Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat. Genet. (1998) 20:175–179.
  • ••Provided evidence that hereditaryprostate cancer genes might reside on the X chromosome (Xq27–28).
  • TAVTIGIAN SV, SIMARD J, TENG DH et al.: A candidate prostate cancer susceptibility gene at chromosome 17p. Nat. Genet. (2001) 27:172–180.
  • ••Identified ELAC2 gene harbouringmutations that segregate with prostate cancer in two pedigrees.
  • KORVER W, GUEVARA C, CHEN Y et al.: The product of the candidate prostate cancer susceptibility gene ELAC2 interacts with the 7-tubulin complex. Int. J. Cancer (2003) 104:283–288.
  • JANI AB, HELLMAN S: Early prostate cancer: clinical decision-making. Lancet (2003) 361:1045–1053.
  • MARTEL CL, GUMERLOCK PH, MEYERS FJ, LARA PN: Current strategies in the management of hormone refractory prostate cancer. Cancer Treat. Rev (2003) 29:171–187.
  • WILSON MJ, NORRIS H, WOODSON M, SINHA AA, ESTENSEN RD: Effects of aging and castration on plasminogen activator and metalloprotease activities in the rat prostate complex. Cell. Mol Biol. Res. (1995) 41:603–612.
  • MIZOKAMI A, SAIGA H, MATSUI T, MITA T, SUGITA A: Regulation of androgen receptor by androgen and epidermal growth factor in a human prostatic cancer cell line, LNCaP. Endocrinol fpn. (1992) 39:235–243.
  • LINDZEY J, GROSSMANN M, KUMAR MV, TINDALL DJ: Regulation of the 5'-flanking region of the mouse androgen receptor gene by cAMP and androgen. Ma Endocrinol (1993) 7:1530–1540.
  • CHAN JM, STAMPFER MJ, GIOVANNUCCI E et al: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science (1998) 279:563–566.
  • HSING AW, REICHARDT JK, STANCZYK FZ: Hormones and prostate cancer: current perspectives and future directions. Prostate (2002) 52:213–235.
  • HUDES GR: Signaling inhibitors in the treatment of prostate cancer. Invest. New Drugs (2002) 20:159–172.
  • WANG L, WHITLATCH LW, FLANAGAN JN, HOLICK ME CHEN TC: Vitamin D autocrine system and prostate cancer. Recent Results Cancer Res. (2003) 164:223–237.
  • SKRYMA RN, PREVARSKAYA NB, DUFY-BARBE L, ODESSA ME AUDIN J, DUFY B: Potassium conductance in the androgen-sensitive prostate cancer cell line, LNCaP: involvement in cell proliferation. Prostate (1997) 33:112–122.
  • •Demonstrated a role for potassium channels in prostate cancer cell proliferation.
  • OUADID-AHID OUCHH, VAN COPPENOLLE F, LE BOURHIS X, BELHAJ A, PREVARSKAYA N: Potassium channels in rat prostate epithelial cells. FEBS Lett. (1999) 459:15–21.
  • LANIADO ME, FRASER SP, DJAMGOZ MB: Voltage-gated K+ channel activity in human prostate cancer cell lines of markedly different metastatic potential: distinguishing characteristics of PC-3 and LNCaP cells. Prostate (2001) 46:262–274.
  • KIM JH, HONG EK, CHOI HS et al: K* channel currents in rat ventral prostate epithelial cells. Prostate (2002) 51:201–210.
  • ABDUL M, HOOSEIN N: Expression and activity of potassium ion channels in human prostate cancer. Cancer Lett. (2002) 186:99–105.
  • •Demonstrated that I(' channel modulators could alter prostate cancer cell proliferation.
  • SMITH RD, GOLDIN AL: Functional analysis of the rat I sodium channel in xenopus oocytes. Neurosci. (1998) 18:811–820.
  • GRIMES JA, DJAMGOZ MB: Electrophysiological characterization of voltage-gated Na* current expressed in the highly metastatic Mat-LyLu cell line of rat prostate cancer. J. Cell. Physiol (1998) 175:50–58.
  • DISS JK, ARCHER SN, HIRANO J, FRASER SP, DJAMGOZ MB: Expression profiles of voltage-gated Na' channel a-subunit genes in rat and human prostate cancer cell lines. Prostate (2001) 48:165–178.
  • GUTIERREZ AA, ARIAS JM, GARCIA L, MAS-OLIVA J, GUERRERO-HERNANDEZ A: Activation of a Ca2'-permeable cation channel by two different inducers of apoptosis in a human prostatic cancer cell line. Physiol (1999) 517:95–107.
  • TSAVALER L, SHAPERO MH, MORKOWSKI S, LAUS R: Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res. (2001) 61:3760–3769.
  • PANE SG: The growth regulatory fibroblast IK channel is the prominent electrophysiological feature of rat prostatic cancer cells. Biochein. Biophys. Res. Commun. (2000) 269:457–463.
  • PARIHAR AS, COGHLAN MJ, GOPALAKRISHNAN M, SHIEH CC: Effects of intermediate-conductance Ca2'-activated K+ channel modulators on human prostate cancer cell proliferation. Eur. Pharmacol (2003) 471:157–164.
  • LOGSDON NJ, KANG J, TOGO JA, CHRISTIAN EP, AIYAR J: A novel gene, hKCa4, encodes the calcium-activated potassium channel in human T lymphocytes. I Biol. Chem. (1997) 272:32723–32726.
  • FRASER SP, GRIMES JA, DJAMGOZ MB: Effects of voltage-gated ion channel modulators on rat prostatic cancer cell proliferation: comparison of strongly and weakly metastatic cell lines. Prostate (2000) 44:61–76.
  • RYBALCHENKO V, PREVARSKAYA N, VAN COPPENOLLE F et al: Verapamil inhibits proliferation of LNCaP human prostate cancer cells influencing K+ channel gating. Ma Pharmacol (2001) 59:1376–1387.
  • KOTECHA SA, SCHLICHTER LC: A Kv1.5 to Kv1.3 switch in endogenous hippocampal microglia and a role in proliferation. Neurosci. (1999) 19:10680–10693.
  • KHANNA R, CHANG MC, JOINER WJ, KACZMAREK LK, SCHLICHTER LC: hSK4/hIK1, a calmodulin-binding Ka channel in human T lymphocytes. Roles in proliferation and volume regulation. Biol. Chem. (1999) 274:14838–14849.
  • JENSEN BS, ODUM N, JORGENSEN NK, CHRISTOPHERSEN P, OLESEN SP: Inhibition ofT cell proliferation by selective block of Ca2+-activated K+ channels. Proc Nati Acad. Sci. USA (1999) 96:10917–10921.
  • GHANSHANI S, WULFF H, MILLER MJ et al.: Up-regulation of the IKcal potassium channel during T-cell activation. Molecular mechanism and functional consequences. J. Biol. Chem. (2000) 275:37137–37149.
  • LEGRAND G, HUMEZ S, SLOMIANNY C et al.: Ca2+ pools and cell growth. Evidence for sarcoendoplasmic Ca2+-ATPases 2B involvement in human prostate cancer cell growth control. J. Biol. Chem. (2001) 276:47608–47614.
  • SCHLICHTER L, SIDELL N, HAGIWARA S: Potassium channels mediate killing by human natural killer cells. Proc. Natl. Acad. Sci. USA (1986) 83:451–455.
  • LU X, FEIN A, FEINSTEIN MB, O'ROURKE FA: Antisense knock out of the inositol 1, 3,4,5-tetrakisphosphate receptor GAP1(IP4BP) in the human erythroleukemia cell line leads to the appearance of intermediate conductance Ka channels that hyperpolarize the membrane and enhance calcium influx. Gen. Physiol (1999) 113:81–96.
  • FANGER CM, RAUER H, NEBEN AL et al.: Calcium-activated potassium channels sustain calcium signaling in T lymphocytes. Selective blockers and manipulated channel expression levels. Biol. Chem. (2001) 276:12249–12256.
  • BENZAQUEN LR, BRUGNARA C, BYERS HR, GATTON-CELLI S, HALPERIN JA: Clottimazole inhibits cell proliferation M vitro and in vivo. Nat. Med. (1995) 1:534–540.
  • WULFF H, MILLER MJ, HANSEL W, GRISSMER S, CAHALAN MD, CHANDY KG: Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K* channel, IKcal: a potential immunosuppressant. Proc. Nat] Acad. ScL USA (2000) 97:8151–8156.
  • BEETON C, WULFF H, BARBARIA J et al.: Selective blockade of T lymphocyte K* channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc. Natl. Acad. Sci. USA (2001) 98:13942–13947.
  • KOHLER R, WULFF H, EICHLER I et al: Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation (2003) 108:1119–1125.
  • STOCKER JW, DE FRANCESCHI L, MCNAUGHTON-SMITH GA, CORROCHER R, BEUZARD Y, BRUGNARA C: ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. Blood(2003) 101:2412–2418.
  • BIVALACQUA TJ, CHAMPION HC, HELLSTROM WJ, KADOWITZ PJ: Pharmacotherapy for erectile dysfunction. Trends Phannacol Sci. (2000) 21:484–489.
  • •A comprehensive review of erectile dysfunction.
  • ANDERSSON KE: Pharmacology of penile erection. Pharinacol Rev (2001) 53:417–450.
  • •A comprehensive review of the pharmacology of penile erection.
  • NEHRA A, STEERS WD, ALTHOF SE et al.: Third international conference on the management of erectile dysfunction: linking pathophysiology and therapeutic response. Urol. (2003) 170:S3–S5.
  • ANDERSSON KE: Erectile physiological and pathophysiological pathways involved in erectile dysfunction. J. Urol. (2003) 170:S6–S13.
  • FELDMAN HA, GOLDSTEIN I, HATZICHRISTOU DG, KRANE RJ, MCKINLAY JB: Construction of a surrogate variable for impotence in the Massachusetts Male Aging Study. Clin. Epideiniol (1994) 47:457–467.
  • MCKINLAY JB: The worldwide prevalence and epidemiology of erectile dysfunction. Int. J. Lamm. Res. (2000) 12:S6–S11.
  • MEULEMAN EJ: Prevalence of erectile dysfunction: need for treatment? hat. J. Impot. Res. (2002) 14:S22–S28.
  • SEFTEL AD: Erectile dysfunction in the elderly: epidemiology, etiology and approaches to treatment. Urol. (2003) 169:1999–2007.
  • LAUMANN EO, PAIK A, ROSEN RC: The epidemiology of erectile dysfunction: results from the National Health and Social Life Survey. Int. J. Impot. Res. (1999) 11:S60–S64.
  • UN CS, HO HC, GHOLAMI S, CHEN KC, JAD A, LUE TF: Gene expression profiling of an arteriogenic impotence model. Biochein. Biophys. Res. Commun. (2001) 285:565–569.
  • •A study of gene expression profile in an arteriogenic impotence model.
  • USER HM, ZELNER DJ, MCKENNA KE, MCVARY KT: Microarray analysis and description of SMR1 gene in rat penis in a post-radical prostatectomy model of erectile dysfunction. Urol. (2003) 170:298–301.
  • SOMLYO AP, SOMLYO AV: Ca2' sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev (2003) 83:1325–1358.
  • CHITALEY K, WINGARD CJ, CLINTON WEBB R et al.: Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat. Med. (2001) 7:119–122.
  • HAAS CA, SEFTEL AD, RAZMJOUEI K, GANZ MB, HAMPEL N, FERGUSON K: Erectile dysfunction in aging: upregulation of endothelial nitric oxide synthase. Urology(1998) 51:516–522.
  • FERRINI M, MAGEE TR, VERNET D, RAJFER J, GONZALEZ-CADAVID NF: Aging-related expression of inducible nitric oxide synthase and markers of tissue damage in the rat penis. Biol. Reprod. (2001) 64:974–982.
  • CHRIST GJ, SPRAY DC, BRINK PR: Characterization of K currents in cultured human corporal smooth muscle cells. J. Andra (1993) 14:319–328.
  • FAN SF, BRINK PR, MELMAN A, CHRIST GJ: An analysis of the Maxi-K* (Ka) channel in cultured human corporal smooth muscle cells. J. Urol. (1995) 153:818–825.
  • MALYSZ J, GIBBONS SJ, MILLER SM et al.: Potassium outward currents in freshly dissociated rabbit corpus cavernosum myocytes. Urol. (2001) 166:1167–1177.
  • MALYSZ J, FARRUGIA G, OU Y, SZURSZEWSKI JH, NEHRA A, GIBBONS SJ: The Kv2.2 a subunit contributes to delayed rectifier K* currents in myocytes from rabbit corpus cavernosum. Andra (2002) 23:899–910.
  • •Molecular identification of Kv2.2 as a major delayed-rectifier IQ- channel in rabbit corpus cavernosum myocytes.
  • ARCHER SL: Potassium channels and erectile dysfunction. Vasco] Pharmacol (2002) 38:61–71.
  • HOLMQUIST F, ANDERSSON KE, FOVAEUS M, HEDLUND H: K'-channel openers for relaxation of isolated penile erectile tissue from rabbit. Urol. (1990) 144:146–151.
  • HEDLUND P, HOLMQUIST F, HEDLUND H, ANDERSSON KE: Effects of nicorandil on human isolated corpus cavernosum and cavernous artery. Urol. (1994) 151:1107–1113.
  • VENKATESWARLU K, GIRALDI A, ZHAO W et al.: Potassium channels and human corporeal smooth muscle cell tone: diabetes and relaxation of human corpus cavernosum smooth muscle by adenosine triphosphate sensitive potassium channel openers. J. Urol. (2002) 168:355–361.
  • ••Demonstrated that corpus cavemosurnsmooth muscle strips from patients without diabetes are more sensitive to KCO-induced muscle relaxation than those with diabetes.
  • INSUK SO, CHAE MR, CHOI JVV, YANG DK, SIM JH, LEE SW: Molecular basis and characteristics of KATp channel in human corporal smooth muscle cells. Int. J. Impot. Res. (2003) 15:258–266.
  • •Provided molecular identification of KATp channel subunits in human corporal smooth muscle cells.
  • TRIGO-ROCHA F, DONATUCCI CF, HSU GL, NUNES L, LUE TF, TANAGHO EA: The effect of intracavernous injection of potassium channel openers in monkeys and dogs. Int. J. Impot. Res. (1995) 7:41–48.
  • MOON DG, BYUN HS, KIM JJ: A KATp-channel opener as a potential treatment modality for erectile dysfunction. BIU Int. (1999) 83:837–841.
  • CAVALLINI G: Mincoddil versus nitroglycerin: a prospective double-blind controlled trial in transcutaneous erection facilitation for organic impotence. Urol. (1991) 146:50–53.
  • RADOMSKI SB, HERSCHORN S, RANGASWAMY S: Topical minoxidil in the treatment of male erectile dysfunction. J Um/. (1994) 151:1225–1226.
  • VICK RN, BENEVIDES M, PATEL M, PARIVAR K, LINNET O, CARSON CC: The efficacy, safety and tolerability of intracavernous PNU-83757 for the treatment of erectile dysfunction. Urol. (2002) 167:2618–2623.
  • LEE SW, KANG TM: Effects of nitric oxide on the Ca2'-activated potassium channels in smooth muscle cells of the human corpus cavernosum. Urol. Res. (2001) 29:359–365.
  • SPEKTOR M, RODRIGUEZ R, ROSENBAUM RS, WANG HZ, MELMAN A, CHRIST GJ: Potassium channels and human corporeal smooth muscle cell tone: further evidence of the physiological relevance of the Maxi-K channel subtype to the regulation of human corporeal smooth muscle tone in vitro. Urol. (2002) 167:2628–2635.
  • MELMAN A, ZHAO W, DAVIES KP, BAKAL R, CHRIST GJ: The successful long-term treatment of age-related erectile dysfunction with hSlo cDNA in rats in vivo. I Urol. (2003) 170:285–290.
  • GUTMAN GA, CHANDY KG, ADELMAN JP et al.: International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels. Phannacol. Rev (2003) 55:583–586.

Websites

  • http://www.astrazeneca.com Pipeline summary January 29 2004. Accessed: March 1 2004.
  • http://www.neurosearch.com Drug discovery portfolio. SK/IK channel openers, urinary incontinence. Accessed: March 1 2004.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.